HSC-3 Xenograft Model Service for Head and Neck Cancer

The HSC-3 cell line, established from a highly metastatic human squamous cell carcinoma of the tongue, provides a highly metastatic and clinically relevant in vivo platform for investigating oral cavity cancers and assessing the therapeutic efficacy of novel targeted therapies. As a leading pre-clinical contract research organization, Alfa Cytology delivers a comprehensive, turn-key HSC-3 Xenograft Model Service that combines scientific precision with reliable experimental execution to accelerate your head and neck cancer drug discovery pipelines.

Overview of HSC-3 Xenograft Model for Head and Neck Cancer

The HSC-3 xenograft model is an indispensable in vivo translation platform extensively utilized in head and neck squamous cell carcinoma (HNSCC) research, specifically for evaluating aggressive and metastatic malignancies of the oral cavity. By inoculating human HSC-3 tongue squamous cell carcinoma cells into immunodeficient mice, this model accurately recapitulates the histological characteristics, high invasive potential, and complex microenvironmental interactions observed in advanced human oral cancers.

Biologically, the HSC-3 model is characterized by its exceptionally rapid growth kinetics and high propensity for local lymph node metastasis, making it a premier choice for investigators studying tumor dissemination and anti-metastatic therapeutics. It retains key molecular driver profiles of human tongue carcinomas, including altered matrix metalloproteinase (MMP) expressions and specific signaling pathway activations that drive epithelial-mesenchymal transition (EMT). Consequently, this model is a global standard for evaluating the therapeutic potency of small-molecule kinase inhibitors, monoclonal antibodies, immunotherapies, and combination regimens aimed at halting tumor growth and metastatic progression.

Fig 1. Effects of piperine on the induction of apoptosis and autophagy through the PI3K/Akt/mTOR pathway in HSC-3 cells. (Han EJ, et al., 2023)

Cell Line Information: HSC-3

The HSC-3 cell line was derived from a primary tumor biopsy of a human squamous cell carcinoma of the tongue, exhibiting a high metastatic frequency to mandibular lymph nodes. These cells present an adherent, epithelial morphology under standard in vitro culture conditions and provide a robust genomic profile representing highly aggressive HNSCC.

Our Services

Workflow of HSC-3 Xenograft Model Construction

• Cell Culture & Quality Control: Human HSC-3 cells are expanded in vitro using certified nutrient growth media under optimized, strictly monitored environmental parameters. Comprehensive quality control profiling, consisting of mandatory Short Tandem Repeat (STR) authentication and mycoplasma clearance testing, is performed prior to harvesting to guarantee total phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are carefully selected based on the specific requirements of the study design. The animals are housed within controlled facility parameters for a designated adaptation period to establish stable physiological baselines and ensure optimal health parameters.
• Precision Inoculation: A calibrated suspension of high-viability HSC-3 cells is prepared and blended with a validated biological matrix carrier to optimize spatial cell distribution and support initial engraftment. The cellular mixture is precisely injected in vivo into target cohorts via subcutaneous or orthotopic tongue routes, depending on whether local invasion or metastatic tracking is required.
• Longitudinal Growth Tracking: Following successful model establishment and tumor validation, growth kinetics are tracked systematically using high-precision digital calipers under continuous health monitoring. Animal body weights, physiological baselines, and general behavior are routinely cataloged to establish a dependable and comprehensive growth profile.
• Stratification & Dosing: Once the expanding tumor volumes reach a predetermined, statistically optimal range, the animals are randomized into specific therapeutic cohorts. This stratification step perfectly balances baseline tumor parameters across all groups before customized dosing and efficacy evaluation protocols begin.

Fig 2. HSC-3 Xenograft Model Construction Workflow

Case Study - HSC-3 Xenograft Model Development

In a recent pre-clinical validation program, an HSC-3 xenograft model was constructed to evaluate a novel targeted therapeutic agent designed to inhibit tumor invasion and metastasis. Following precision subcutaneous inoculation of human HSC-3 cells into immunodeficient mice, the tumors achieved a uniform engraftment rate exceeding 90% and exhibited rapid, aggressive growth kinetics over a 24-day monitoring timeline. Tumor-bearing animals randomized into the treatment cohort demonstrated a statistically significant, dose-dependent reduction in both primary tumor volume and regional lymph node involvement compared to control groups, validating the model's high predictive reliability and exceptional sensitivity for screening advanced head and neck cancer therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of advanced squamous cell carcinoma models, providing reliable in vivo platforms for complex head and neck cancer studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your head and neck oncology pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing the HSC-3 platform, please reach out to us today. The dedicated scientific team at Alfa Cytology is fully prepared to assist you with experimental design, provide operational insights, and deliver the high-quality data your pipeline needs to succeed; please feel free to contact us to get started.

For research use only. Not intended for any clinical use.